• Bristol and Nottingham universities found that a single molecule plays a crucial role in the forming of new blood vessels which tumors need in order to survive
  • Because the treatment targets blood vessels, it is likely it could be used for other types of cancer and even for a potential cure to blindness
  • Biotech company Exonate, a spin-out drug development company from the University of Nottingham, aims to develop SRPK1 inhibitors

Share This Article